AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03974126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80 grams of starch
Description: 80 grams of starch in form of white bread to be consumed within 15 minutes
Study NCT01570517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IASD System
Description: Implantation of the DC Devices Inc. IASD System
Study NCT02205268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy neurofeedback training
Study NCT01222988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Optifast Products
Description: Optional Optifast products offered once every other week X 6 months; then monthly.
Study NCT00920361 — intervention group
Intervention type: DRUG
Intervention: Follitropin beta
Description: Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
Study NCT04080492 — intervention group
Intervention type: OTHER
Intervention: QOL Survey
Description: The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
Study NCT04351932 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow & adipose mesenchymal stem cells injection
Description: intrarticular bone marrow and adipose stem cells injection.
Study NCT04469088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.
Study NCT04469088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy Treatment
Description: Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
Study NCT03632460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: epidural administration of dexmedetomidine added to ropivacaine
Study NCT03998800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
Study NCT03998800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement
Description: Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
Study NCT03998800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance exercise on a cycle ergometer
Description: On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
Study NCT03998800 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Endurance exercise on a cycle ergometer
Description: On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
Study NCT04715841 — intervention group
Intervention type: OTHER
Intervention: gait assessment
Description: gait assessment were done using 3DMA system
Study NCT04224233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based physical activity programme
Description: iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
Study NCT04224233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive a leaflet with exercises and PA recommendations.
Study NCT00222755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease Management
Description: Self-management, care management, guidelines
Study NCT04154384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Care Specialist (LCS) Intervention
Description: The Life Care Specialist (LCS) uses a two-arm approach to education by initially assessing participants general understanding of opioids upon which targeted education is tailored and applied and secondly, building a longitudinal relationship with each patient to increase the saliency of administered opioid education during postoperative follow-up. Information includes proper disposal, common symptoms of opioid use, signs of dependence and overdose and use of naloxone. Information is disseminated orally with adjunct physical resource guides including visual representations and literature.
Study NCT01977248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor Affect Relationship-based Therapy (SMART)
Description: The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
Study NCT03879993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Resistance training 3 times per week (45-60 minutes of resistance training)
Study NCT04472637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin 10 mg, as one tablet /day for 24 weeks.
Study NCT04472637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks)
Study NCT00555568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: recovery oriented mental health peer support group
Description: This is a recovery-focused mental health education and support group led by peer facilitators
Study NCT00555568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: recovery-oriented mental health clinician-led group
Description: This is a recovery-focused mental health education and support group led by a mental health clinician
Study NCT03636308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nanoparticle albumin-bound paclitaxel
Description: Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
Study NCT03636308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
Study NCT03636308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
Study NCT03636308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
Study NCT02687360 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS treatment
Description: In the active treatment, magnetic power output will be delivered to the participants through the coils.
Study NCT02687360 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS treatment
Description: The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
Study NCT01726816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol 250mg/day
Description: Probucol 250mg + Placebo
Study NCT01726816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol 500mg/day
Description: Probucol 500mg + Placebo
Study NCT01726816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probucol matching placebo
Study NCT04486989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Conditioning Protocol
Description: Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
Study NCT04486989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voice Production Exercises
Description: Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
Study NCT02031198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AADvac1
Description: Active immunization against pathological Alzheimer's disease tau protein
Study NCT01385319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal stent implantation
Description: After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month.
Study NCT01385319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zotarolimus eluting stent
Description: After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month.
Study NCT03380000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
Study NCT03380000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice placebo
Description: This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
Study NCT00947934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
Study NCT00106340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Study NCT00002657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: 5 mg/m\^2
Study NCT02144415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-1020 400 mg
Description: 4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
Study NCT02144415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-1020 800 mg
Description: 8 x EB-1020 100-mg capsules
Study NCT00002657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: 3.0 x 10\^6 IU/m\^2
Study NCT00002657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 650 mg/m\^2
Study NCT00002657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 300 mg/m\^2
Study NCT02144415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine 150 mg
Description: 3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
Study NCT02144415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-amphetamine 40 mg
Description: 4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
Study NCT00002657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 25 mg/m\^2
Study NCT00002657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 120 mg/m\^2
Study NCT00002657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 120 mg/m\^2
Study NCT00002657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: dose varies during initial immunosuppression. During chemotherapy, 60 mg/m\^2.
Study NCT00002657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m\^2
Study NCT00002657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Simple excision, for those patients who have resectable disease after initial immunosuppression.
Study NCT00002657 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: For treatment of localized disease that remains after initial immunosuppression.
Study NCT01349296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus + BIBF 1120
Description: Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
Study NCT02144415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 x matching placebo capsules
Study NCT00491816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib with neoadjuvant chemotherapy
Description: 150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
Study NCT03268369 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI of the brain
Description: to eliminate a structural intra-cerebral lesion
Study NCT00719992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography
Description: effect of level of HS-CRP
Study NCT00719992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: effect of level of HS-CRP
Study NCT02162654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
Study NCT02691481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oatmeal breakfast
Study NCT02691481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna formula
Study NCT02691481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ultra Glucose Control formula
Study NCT01626534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600mg loading dose then 75mg/day
Study NCT01626534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trigagrelor
Description: 180 mg loading dose then 90 mg Twice a day
Study NCT03507192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle relaxation using full body massage machine
Description: Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
Study NCT04447924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bif195
Description: Daily intake of Bif195 dietary supplement
Study NCT04447924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of Placebo
Study NCT00435149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release surgery
Description: Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
Study NCT00435149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release surgery
Description: Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
Study NCT06276842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block
Description: Administration of a local anesthetic agent around the inferior alveolar nerve to achieve anesthesia in the mandibular region.
Study NCT06276842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Infiltration
Description: Administration of a local anesthetic agent into the tissue adjacent to the tooth being treated to achieve localized anesthesia.
Study NCT06276842 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block and Buccal Infiltration
Description: Utilization of both the Inferior Alveolar Nerve Block and Buccal Infiltration techniques simultaneously for anesthesia in the mandibular region.
Study NCT03066297 — intervention group
Intervention type: PROCEDURE
Intervention: Extent of pulmonary resection
Description: Extent of pulmonary resection selected based on the institutional decision-making algorithm
Study NCT03268369 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI of the brain
Description: to eliminate a structural intra-cerebral lesion
Study NCT03268369 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET scan [18F]F-A-85380
Description: exam performed after iv injection of 200 MBq \[18F\]F-A-85380
Study NCT03268369 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan [18F]F-A-85380
Description: exam performed after iv injection of 200 MBq \[18F\]F-A-85380
Study NCT00809861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: volar locking plating
Description: open reduction and internal fixation
Study NCT00809861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external immobilisation
Description: closed reduction and external fixation
Study NCT02883920 — intervention group
Intervention type: OTHER
Intervention: Allergy and respiratory functional tests